{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:03:16Z","timestamp":1784962996260,"version":"3.55.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This retrospective, real-world study evaluated the prevalence of brain metastases, clinicodemographic characteristics, systemic treatments, and factors associated with overall survival among patients with advanced non\u2013small cell lung cancer (aNSCLC) in the US. We also described the genomic characterization of 180 brain metastatic specimens and frequency of clinically actionable genes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>De-identified electronic health records-derived data of adult patients diagnosed with aNSCLC between 2011 and 2017 were analyzed from a US-nationwide clinicogenomic database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 3257 adult patients with aNSCLC included in the study, approximately 31% (n = 1018) had brain metastases. Of these 1018 patients, 71% (n = 726) were diagnosed with brain metastases at initial NSCLC diagnosis; 57% (n = 583) of patients with brain metastases received systemic treatment. Platinum-based chemotherapy combinations were the most common first-line therapy; single-agent chemotherapies, epidermal growth factor receptor tyrosine kinase inhibitors, and platinum-based chemotherapy combinations were used in second line. Patients with brain metastases had a 1.56 times greater risk of death versus those with no brain metastases. In the brain metastatic specimens (n = 180), a high frequency of genomic alterations in the p53, MAPK, PI3K, mTOR, and cell-cycle associated pathways was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The frequency of brain metastases at initial clinical presentation and associated poor prognosis for patients in this cohort underscores the importance of early screening for brain metastasis in NSCLC. Genomic alterations frequently identified in this study emphasize the continued need for genomic research and investigation of targeted therapies in patients with brain metastases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad170","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:47:39Z","timestamp":1687798059000},"page":"e1075-e1091","source":"Crossref","is-referenced-by-count":8,"title":["Clinicogenomic factors and treatment patterns among patients with advanced non\u2013small cell lung cancer with or without brain metastases in the United States"],"prefix":"10.1093","volume":"28","author":[{"given":"Emily Nash","family":"Smyth","sequence":"first","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincy","family":"John","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon V","family":"Tiu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda Dale","family":"Willard","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Lilly Global Clinical Development, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Kay","family":"Beyrer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Bowman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Value Evidence Outcomes - Research, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Han","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Statistics RWE, Indianapolis, IN 46225 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Divisions of Hematology\/Oncology and Neuro-Oncology , Massachusetts General Hospital, Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"1","key":"2023110708504980400_CIT0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin."},{"issue":"11","key":"2023110708504980400_CIT0002","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/ijc.29915","article-title":"Targeted therapies for treatment of non-small cell lung cancer\u2014recent advances and future perspectives","volume":"138","author":"Minguet","year":"2016","journal-title":"Int J Cancer."},{"issue":"5","key":"2023110708504980400_CIT0003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc."},{"issue":"20","key":"2023110708504980400_CIT0004","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.32372","article-title":"Genes associated with increased brain metastasis risk in non-small cell lung cancer: comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)","volume":"125","author":"Wang","year":"2019","journal-title":"Cancer."},{"issue":"9","key":"2023110708504980400_CIT0005","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/2211-5463.12501","article-title":"Characterization of genetic alterations in brain metastases from non-small cell lung cancer","volume":"8","author":"Liao","year":"2018","journal-title":"FEBS Open Bio."},{"key":"2023110708504980400_CIT0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2020.03.006","article-title":"Systemic treatment of brain metastases in non-small cell lung cancer","volume":"132","author":"Page","year":"2020","journal-title":"Eur J Cancer."},{"issue":"23","key":"2023110708504980400_CIT0007","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","article-title":"CNS metastases in breast cancer: old challenge, new frontiers","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2023110708504980400_CIT0008","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.21037\/apm-20-1722","article-title":"Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med."},{"issue":"1","key":"2023110708504980400_CIT0009","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13041-021-00886-4","article-title":"Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases","volume":"14","author":"Xu","year":"2021","journal-title":"Mol Brain"},{"key":"2023110708504980400_CIT0010","author":"National Comprehensive Cancer Network"},{"issue":"5","key":"2023110708504980400_CIT0011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"uppl 5","key":"2023110708504980400_CIT0012","first-page":"v35","article-title":"Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles","volume":"3","author":"Steindl","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"139","key":"2023110708504980400_CIT0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1183\/16000617.0071-2015","article-title":"KRAS oncogene in lung cancer: focus on molecularly driven clinical trials","volume":"25","author":"Kempf","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"15_suppl","key":"2023110708504980400_CIT0014","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/jco.2013.31.15_suppl.8000","article-title":"Intergroupe Francophone de Cancerologie Thoracique. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol."},{"issue":"11","key":"2023110708504980400_CIT0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in non-small cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J Oncol Pract"},{"key":"2023110708504980400_CIT0016","author":"Tagrisso\u00ae (osimertinib) tablets [package insert]"},{"issue":"13","key":"2023110708504980400_CIT0017","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med."},{"issue":"750031","key":"2023110708504980400_CIT0018","doi-asserted-by":"crossref","first-page":"750031","DOI":"10.3389\/fphar.2021.750031","article-title":"Experimental study of almonertinib crossing the blood-brain barrier in EGFR-mutant NSCLC brain metastasis and spinal cord metastasis models","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol."},{"issue":"1","key":"2023110708504980400_CIT0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of Osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"33","key":"2023110708504980400_CIT0020","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online ahead of print, 2018 Aug 28]","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol."},{"issue":"15","key":"2023110708504980400_CIT0021","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of Adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2023110708504980400_CIT0022","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA."},{"issue":"31","key":"2023110708504980400_CIT0023","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023110708504980400_CIT0024","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"2023110708504980400_CIT0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11060-016-2057-5","article-title":"Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer","volume":"127","author":"Yuan","year":"2016","journal-title":"J Neurooncol."},{"issue":"4","key":"2023110708504980400_CIT0026","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr Oncol"},{"issue":"6","key":"2023110708504980400_CIT0027","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol"},{"issue":"5","key":"2023110708504980400_CIT0028","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1377\/hlthaff.2017.1579","article-title":"Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study","volume":"37","author":"Agarwala","year":"2018","journal-title":"Health Aff (Millwood)."},{"key":"2023110708504980400_CIT0029","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"Medrxiv"},{"issue":"11","key":"2023110708504980400_CIT0030","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"2023110708504980400_CIT0031","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/cancers12123707","article-title":"Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a \u201creal-life\u201d setting","volume":"12","author":"Skribek","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2023110708504980400_CIT0032","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21818","article-title":"Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis","volume":"106","author":"Hu","year":"2006","journal-title":"Cancer."},{"issue":"4","key":"2023110708504980400_CIT0033","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuonc\/nos004","article-title":"Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma","volume":"14","author":"Bailon","year":"2012","journal-title":"Neuro Oncol"},{"issue":"8","key":"2023110708504980400_CIT0034","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): aNon randomized Phase II Study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"21","key":"2023110708504980400_CIT0035","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.25254","article-title":"Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer","volume":"116","author":"Hubbs","year":"2010","journal-title":"Cancer."},{"issue":"3","key":"2023110708504980400_CIT0036","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.lungcan.2015.11.011","article-title":"Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study","volume":"90","author":"Moro-Sibilot","year":"2015","journal-title":"Lung Cancer."},{"issue":"30","key":"2023110708504980400_CIT0037","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol."},{"issue":"22","key":"2023110708504980400_CIT0038","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.2217\/fon-2021-0230","article-title":"Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy","volume":"17","author":"Stenehjem","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"2023110708504980400_CIT0039","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12890-020-01270-z","article-title":"Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative","volume":"20","author":"Soares","year":"2020","journal-title":"BMC Pulm Med."},{"issue":"11","key":"2023110708504980400_CIT0040","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol."},{"issue":"suppl 5","key":"2023110708504980400_CIT0041","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol."},{"issue":"6","key":"2023110708504980400_CIT0042","doi-asserted-by":"crossref","first-page":"e0178420","DOI":"10.1371\/journal.pone.0178420","article-title":"Real-world first-line treatment and overall survival in non-small-cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting","volume":"12","author":"Abernethy","year":"2017","journal-title":"PLoS One."},{"issue":"8","key":"2023110708504980400_CIT0043","doi-asserted-by":"crossref","first-page":"e180798","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O\u2019Connor","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023110708504980400_CIT0044","article-title":"567 - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","author":"Ramalingam","year":"2019"},{"issue":"3","key":"2023110708504980400_CIT0045","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2023110708504980400_CIT0046","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive nonsmall-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol."},{"issue":"12","key":"2023110708504980400_CIT0047","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"21","key":"2023110708504980400_CIT0048","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med."},{"key":"2023110708504980400_CIT0049","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/CMAR.S63603","article-title":"A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer","volume":"6","author":"Cuy\u00fan Carter","year":"2014","journal-title":"Cancer Manag Res"},{"issue":"6","key":"2023110708504980400_CIT0050","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.12669\/pjms.38.6.5457","article-title":"Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer","volume":"38","author":"Ran","year":"2022","journal-title":"Pak J Med Sci"},{"issue":"20","key":"2023110708504980400_CIT0051","doi-asserted-by":"crossref","first-page":"33922","DOI":"10.18632\/oncotarget.15412","article-title":"Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2023110708504980400_CIT0052","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/s12885-021-08713-8","article-title":"Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data","volume":"21","author":"Guti\u00e9rrez","year":"2021","journal-title":"BMC Cancer"},{"issue":"13","key":"2023110708504980400_CIT0053","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin Cancer Res."},{"key":"2023110708504980400_CIT0054","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","article-title":"Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11","volume":"130","author":"La Fleur","year":"2019","journal-title":"Lung Cancer."},{"issue":"4","key":"2023110708504980400_CIT0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/neuonc\/noaa233","article-title":"Population-based estimates of survival among elderly patients with brain metastases","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"2023110708504980400_CIT0056","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","article-title":"Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma","volume":"52","author":"Shih","year":"2020","journal-title":"Nat Genet."},{"issue":"1","key":"2023110708504980400_CIT0057","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","article-title":"High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer","volume":"83","author":"Preusser","year":"2014","journal-title":"Lung Cancer."},{"issue":"10055","key":"2023110708504980400_CIT0058","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet."},{"issue":"12","key":"2023110708504980400_CIT0059","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jtho.2018.09.007","article-title":"Survival comparison in patients with stage IV lung cancer in academic versus community centers in the United States","volume":"13","author":"Ramalingam","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"14","key":"2023110708504980400_CIT0060","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/e1075\/52772203\/oyad170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/e1075\/52772203\/oyad170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:51:43Z","timestamp":1699347103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/11\/e1075\/7207781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad170","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,26]]}}}